Canada · Delayed Price · Currency is CAD Jamieson Wellness Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 16% revenue growth and 18% adjusted EBITDA growth, with strong performance across all markets, especially China. Full-year guidance was reaffirmed, and disciplined capital allocation continues, with inventory investments to support growth and mitigate risks.
Fiscal Year 2025
-
Delivered 12% annual revenue growth and strong Q4 results, led by China and innovation across key markets. 2026 guidance calls for 9–14% revenue growth, stable margins, and continued investment in marketing and product development.
-
Q3 saw 13.2% revenue growth, led by 16.5% branded gains and over 60% growth in China. Guidance for 2025 was raised for branded segments, with strong innovation and digital marketing driving results. Gross margin expanded 350 bps, and no consumer trade-down was observed.
-
Q2 2025 saw 7.7% revenue growth, led by strong branded segment gains in China and the U.S., improved margins, and robust cash flow. Guidance for 2025 was raised for China, with strategic partner outlook lowered due to tariff-related delays. Dividend increased by 9.5%.
-
Q1 2025 saw 14% revenue growth, strong gains in China and international markets, and improved margins. Guidance for 2025 is maintained, with continued investment in innovation, digital, and operational efficiency. Share buybacks and dividends remain key capital priorities.
-
The company has transformed into a global leader, targeting $1 billion in revenue within 3-5 years by expanding in China, the U.S., and internationally while maintaining strong growth in Canada. Deep consumer insights, innovation, and local partnerships drive competitive advantage, with China and U.S. e-commerce as key growth engines.
Fiscal Year 2024
-
Revenue grew 9% to CAD 734M in 2024, with record adjusted EBITDA and strong branded growth. China and international markets delivered standout results, while 2025 guidance calls for 9–14.5% revenue growth and stable margins. Tariff risks are mitigated by supply chain flexibility.
-
Q3 2024 saw 16% revenue growth to CAD 176M, with strong gains in Canada, China, and international markets. Gross margins and adjusted EBITDA improved, and 2024 guidance was narrowed upward. Strategic investments in marketing and innovation continue to drive momentum.
-
Q2 2024 saw 10% revenue growth to CAD 185M, led by 107% growth in China and strong Canadian performance. Gross margin and adjusted EBITDA improved, with an 11% dividend increase announced. Guidance for 2024 and 2025 is maintained, with continued investment in global expansion.